This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback
Trial record 15 of 23 for:    cancer | Studies received from 04/22/2016 to 04/22/2016

A Study of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

This study is not yet open for participant recruitment.
See Contacts and Locations
Verified May 2016 by First People's Hospital of Hangzhou
Sponsor:
Information provided by (Responsible Party):
First People's Hospital of Hangzhou
ClinicalTrials.gov Identifier:
NCT02788058
First received: April 22, 2016
Last updated: May 26, 2016
Last verified: May 2016
  Purpose
To evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy for limited metastatic NSCLC harboring sensitizing EGFR mutations after first line TKI therapy. An exploratory biomarker analysis in blood and tumor samples is also planned.

Condition Intervention Phase
Lung Adenocarcinoma EGFR Positive Non-small Cell Lung Cancer Drug: EGFR-TKI Radiation: Thoracic Hypofractionated Radiotherapy Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Trial of Hypofractionated Radiotherapy for Limited Metastatic NSCLC Harboring Sensitizing EGFR Mutations After First Line TKI Therapy

Resource links provided by NLM:


Further study details as provided by First People's Hospital of Hangzhou:

Primary Outcome Measures:
  • Progression free survival [ Time Frame: 3 years ]

Secondary Outcome Measures:
  • Frequency of T790M mutation before treatment detected by ctDNA [ Time Frame: 1 months ]
  • Abundance of T790M mutation before treatment detected by ctDNA [ Time Frame: 1 months ]
  • Frequency of T790M mutation after radiotherapy detected by ctDNA [ Time Frame: 3 months ]
  • Abundance of T790M mutation after radiotherapy detected by ctDNA [ Time Frame: 3 months ]
  • Frequency of T790M mutation after 1 year detected by ctDNA [ Time Frame: 1 year ]
  • Abundance of T790M mutation after 1 year detected by ctDNA [ Time Frame: 1 year ]
  • Rate of CTCAE grade 2 or higher radiation pneumonitis [ Time Frame: 1 years ]
    We will assess the rate of symptomatic radiation pneumonitis in patients who received the radiation therapy.

  • To assess the short-term quality of life (QOL) [ Time Frame: 4 months ]
    FACT-E score at the 4 months after docetaxel consolidation therapy


Estimated Enrollment: 76
Study Start Date: May 2016
Estimated Study Completion Date: May 2022
Estimated Primary Completion Date: May 2021 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: EGFR-TKI
Patients take EGFR-TKI alone till tumor progression
Drug: EGFR-TKI
Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Other Name: Gefitinib/Erlotinib/Icotinib
Active Comparator: EGFR-TKI+hypofractionated radiotherapy
After 3 mos TKI, patients with limited metastatic take EGFR-TKI concurrent with hypofractionated radiotherapy till tumor progression.
Drug: EGFR-TKI
Gefitinib 250mg po qd or Erlotinib 150mg po qd or Icotinib 125mg po tid
Other Name: Gefitinib/Erlotinib/Icotinib
Radiation: Thoracic Hypofractionated Radiotherapy
40-45 Gy/5-15f

Detailed Description:

Rational:

After inductive TKI therapy in NSCLC with sensitizing EGFR mutations, the residual lesion might be the source of subsequent disease progression, defined as acquired resistance to TKI. Two reasons can be used to explain the formation of the residual lesion:1)there is a subgroup of cancer cells that are not sensitive to TKI therapy because of tumor heterogeneity, like de novo T790M mutation; 2)some cancer cells can keep static state during the beginning treatment, and then develops acquired resistance to TKI therapy under the long-term drug pressure and continue to re-proliferation. From this point of view, elimination of residual lesion provides the chance to reduce or slow the possibility of developing resistance to TKI.

Objective:

To evaluate the efficacy and toxicity of patients treated with hypofractionated radiotherapy for limited metastatic NSCLC harboring sensitizing EGFR mutations after first line TKI therapy. An exploratory biomarker analysis in blood and tumor samples is also planned.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Newly diagnosed metastatic lung adenocarcinoma harboring sensitizing EGFR mutations (L858R, exon 19 deletion), and became oligometastatic disease after 3 months TKI, evaluated by PET/CT scan, brain MRI, and abdomen ultrasound (≤6 discrete lesions of disease, exclusive of the brain metastases, ≤3 lesions in the liver, ≤3 lesions in the lung);
  • All sites of disease must be amenable to definitive RT;
  • An intrathoracic lymph nodal station is considered 1 discrete lesion, according to IASLC lymph nodal station map;
  • Age 18 years or older;
  • ECOG Performance Status 0-2;
  • Adequate bone marrow, liver and renal function, as specified below: Absolute Neutrophil Count (ANC) ≥ 1.5 x 109/L; Hemoglobin ≥ 8 g/dL; Platelets ≥ 100 x 109/L; Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) ; AST and ALT ≤ 2.5 x ULN or ≤ 5 x ULN if liver metastases are present; Serum creatinine ≤ 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min for patients with creatinine levels above institutional normal;
  • For women of child-bearing potential, negative pregnancy test within 14 days prior to starting treatment;
  • Men and women of childbearing age must be willing to use effective contraception while on treatment and for at least 3 months thereafter;
  • Patients and their family signed the informed consents;

Exclusion Criteria:

  • Received chemotherapy before TKI therapy;
  • Brain parenchyma or leptomeningeal disease;
  • Any site of disease that is not amenable to definitive RT;
  • Concurrent malignancies other than non-melanoma skin cancer that require active ongoing treatment;
  • Any medical co-morbidities that would preclude radiation therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02788058

Contacts
Contact: Shenglin Ma, MD 0571-56007908 ext 086 mashenglin@medmail.com.cn

Sponsors and Collaborators
First People's Hospital of Hangzhou
  More Information

Responsible Party: First People's Hospital of Hangzhou
ClinicalTrials.gov Identifier: NCT02788058     History of Changes
Other Study ID Numbers: HZCH-2016-08
Study First Received: April 22, 2016
Last Updated: May 26, 2016

Keywords provided by First People's Hospital of Hangzhou:
Hypofractionated Radiotherapy
EGFR Positive
Lung Adenocarcinoma
Limited Metastases

Additional relevant MeSH terms:
Lung Neoplasms
Bronchial Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Carcinoma, Non-Small-Cell Lung
Adenocarcinoma
Carcinoma, Bronchogenic
Lung Diseases
Respiratory Tract Diseases
Carcinoma
Gefitinib
Erlotinib Hydrochloride
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on June 23, 2017